Hemab Therapeutics Holdings Inc COAG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
-
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
-
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Trading Information
- Previous Close Price
- $32.52
- Day Range
- $29.87–32.56
- 52-Week Range
- $23.00–55.42
- Bid/Ask
- $25.00 / $32.00
- Shares Outstanding
- 46.71M
- Market Cap
- $1.40B
- Volume/Avg
- 351,773 / 462,127
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.hemab.com
Valuation
|
Metric
|
COAG
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.09 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
COAG
|
|---|---|
Quick Ratio | 35.48 |
Current Ratio | 35.85 |
Interest Coverage | — |
Quick Ratio
COAG
Profitability
|
Metric
|
COAG
|
|---|---|
Return on Assets (Normalized) | −28.56% |
Return on Equity (Normalized) | −302.84% |
Return on Invested Capital (Normalized) | −305.76% |
Return on Assets
COAG
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|L$?v@?$ | LOCK|!zV& | $127B | |||
| Moderna Inc
MRNA
| LOCK|&#G%cTJ | LOCK|p?H | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|mBdX>! | LOCK|W!Cl! | $81B | |||
| argenx SE ADR
ARGX
| LOCK|T<?rzY | LOCK|q^ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%$$>#w$ | LOCK|wh# | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|QL?$<m | LOCK|Y?%g | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|p#%QB^vR | LOCK|gVdQ | $27B | |||
| Incyte Corp
INCY
| LOCK|gQZr@%# | LOCK|zmy | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|r?>>&q? | LOCK|k@ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|XF<N#T$ | LOCK|Z@s | $14B |
United States